Anap­tys­Bio clears an ear­ly hur­dle in low-stress PoC study for peanut al­ler­gy med -- big ques­tions go unan­swered

Anap­tys­Bio $ANAB got a big boost out of some ear­ly and pos­i­tive re­sults for its peanut al­ler­gy med ANB020. It was a small, short study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA